EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

RORα, a potential tumor suppressor and therapeutic target of breast cancer






International Journal of Molecular Sciences 13(12): 15755-15766

RORα, a potential tumor suppressor and therapeutic target of breast cancer

The function of the nuclear receptor (NR) in breast cancer progression has been investigated for decades. The majority of the nuclear receptors have well characterized natural ligands, but a few of them are orphan receptors for which no ligand has been identified. RORα, one member of the retinoid orphan nuclear receptor (ROR) subfamily of orphan receptors, regulates various cellular and pathological activities. RORα is commonly down-regulated and/or hypoactivated in breast cancer compared to normal mammary tissue. Expression of RORα suppresses malignant phenotypes in breast cancer cells, in vitro and in vivo. Activity of RORα can be categorized into the canonical and non-canonical nuclear receptor pathways, which in turn regulate various breast cancer cellular function, including cell proliferation, apoptosis and invasion. This information suggests that RORα is a potent tumor suppressor and a potential therapeutic target for breast cancer.


Accession: 055338265

PMID: 23443091

DOI: 10.3390/ijms131215755



Related references

Osborne, C.; Wilson, P.; Tripathy, D., 2004: Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Carcinogenesis is a multistep process characterized by genetic alterations that influence key cellular pathways involved in growth and development. Oncogenes refer to those genes whose alterations cause gain-of-function effects, while tumor suppre...

Reineke, E.L.; Kao, H-Ying., 2009: PML: An emerging tumor suppressor and a target with therapeutic potential. Though originally discovered as a tumor suppressor in Acute Promyelocytic Leukemia (APL), the importance of promyelocytic leukemia protein (PML) in cancers of other origins has not been widely studied. Recent studies have shown that multiple types...

Hu, K.; Law, J.H.; Fotovati, A.; Dunn, S.E., 2013: Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Triple-negative breast cancer (TNBC) high rate of relapse is thought to be due to the presence of tumor-initiating cells (TICs), molecularly defined as being CD44<sup>high</sup>/CD24<sup>-/low</sup>. TICs are resilient to c...

Soussi, T., 1997: Tumor suppressor p53 gene: a potential target for cancer therapy?. Bulletin du Cancer 84(7): 753-756

Farnebo, M.; Bykov, V.J.N.; Wiman, K.G., 2010: The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. The tumor suppressor p53 has been implicated in a growing number of biological processes, including cell cycle arrest, senescence, apoptosis, autophagy, metabolism, and aging. Activation of p53 in response to oncogenic stress eliminates nascent tu...

Reisman, D.; Boggs, K., 2009: Transcriptional regulation of the p53 tumor suppressor gene: a potential target for cancer therapeutics?. The tightly regulated expression of p53 contributes to genomic stability and transcription of the p53 gene is induced prior to cells entering S-phase, possibly as a mechanism to insure a rapid p53 response in the event of DNA damage. We have previ...

Liu, Q.; Jin, J.; Ying, J.; Cui, Y.; Sun, M.; Zhang, L.; Fan, Y.; Xu, B.; Zhang, Q., 2016: Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1 in human renal cell carcinoma and its role as a potential therapeutic target. This study investigated the epigenetic alteration and biological function of the pro-apoptotic gene ASC/TMS1 in renal cell carcinoma. ASC/TMS1 was downregulated in five out of six RCC cell lines. A significant downregulation was also detected in s...

Tsai, M-Feng.; Wang, C-Chung.; Chen, J.Jw., 2014: Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer. Lung cancer is the leading cause of cancer-related mortality throughout the world. Non-small cell lung cancer (NSCLC) accounts for 85% of all diagnosed lung cancers. Despite considerable progress in the diagnosis and treatment of the disease, the...

Bosco, E.E.; Wang, Y.; Xu, H.; Zilfou, J.T.; Knudsen, K.E.; Aronow, B.J.; Lowe, S.W.; Knudsen, E.S., 2006: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G(1)/S-phase cell-cycle progression and is a critical mediator of antipr...

Bosco, E., E.; Wang, Y.; Xu, H.; Zilfou, J., T.; Knudsen, K., E.; Aronow, B., J.; Lowe, S., W.; Knudsen, E., S., 2007: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G(1)/S-phase cell-cycle progression and is a critical mediator of antip...